Summary of Study ST002361

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001516. The data can be accessed directly via it's Project DOI: 10.21228/M8R12T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002361
Study Title	UCP2-dependent redox-sensing in POMC neurons regulates feeding
Study Summary	Paradoxically, glucose, the primary driver of satiety, activates a small population of anorexigenic POMC neurons. Here we show that lactate levels in the circulation and in the cerebrospinal fluid are elevated in fed state and addition of lactate to glucose activates the majority of POMC neurons while increasing cytosolic NADH generation, mitochondrial respiration and extracellular pyruvate levels. Inhibition of lactate dehydrogenases diminishes mitochondrial respiration, NADH production, and POMC neuronal activity. However, inhibition of the mitochondrial pyruvate carrier has no effect. POMC-specific downregulation of Ucp2 (Ucp2PomcKO), a molecule regulated by fatty acid metabolism and shown to play a role as transporter in the malate-aspartate shuttle, abolishes lactate- and glucose-sensing of POMC neurons. Ucp2PomcKO mice have impaired glucose metabolism and are prone to obesity on a high fat diet. Altogether, our data show that lactate through redox signaling and blocking mitochondrial glucose utilization activates POMC neurons to regulate feeding and glucose metabolism.
Institute	Columbia University
Last Name	Diano
First Name	Sabrina
Address	1150 St. Nicholas Avenue Russ Berrie Medical Science Pavilion Rm 405 New York, NY, 10032
Email	sd3449@cumc.columbia.edu
Phone	212 8514554
Submit Date	2022-11-28
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2022-12-15
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002462
Treatment Summary:	We used the inducible Cre/loxP technology to generate mice in which UCP2 was selectively ablated in POMC neurons (Ucp2PomcKO mice). First, mice expressing a tamoxifen-inducible Cre recombinase (CreERT2) in cells expressing POMC (Pomc-CreERT2) were crossed with Rosa26-lox-stop-lox-tdTomato (Ai14; cre-recombinase-dependent expression) mice (Ai14 reporter mice; stock #007914; The Jackson Laboratory) to label POMC-expressing cells. Pomc-CreERT2; Rosa26-lox-stop-lox-tdTomato (Pomc-CreERT2; tdTomato) mice have POMC-expressing cells with the expression of tdTomato by tamoxifen administration. No observation of POMC-tdTomato expression was found in the absence of tamoxifen administration, indicating that recombination was strictly dependent upon tamoxifen-induced Cre recombinase activation. The mice with Pomc-CreERT2; tdTomato were then crossed with mice harboring conditional alleles Ucp2 floxed (Ucp2fl/fl; B6;129S-Ucp2tm2.1Lowl/J, Stock# 022394; The Jackson Laboratory) to generated mice with inducible deletion of Ucp2 specifically in POMC neurons (Ucp2PomcKO mice). All animal experiments were conducted with the mice expressing POMC-CreERT2. As control groups, Ucp2fl/fl; Pomc-CreERT2 mice were injected with tamoxifen, and Ucp2fl/fl; Pomc-CreERT2; tdTomato were mice injected with corn oil (vehicle), and Ucp2fl/fl; Pomc-CreERT2; tdTomato mice were injected intraperitoneally (IP) with tamoxifen (0.1 mg/g BW for 5 consecutive days) starting at 5 weeks of age to induce mature-onset deletion of Ucp2 in POMC neurons of Ucp2PomcKO mice. However, because there were no differences between these two control groups, most of the experiments were performed using Ucp2+/+; Pomc-CreERT2; tdTomato mice injected with tamoxifen (to label POMC neurons with tdTomato expression) as a control group, unless otherwise stated. Body composition was measured in vivo by MRI (EchoMRI; Echo Medical Systems, Houston, TX) monthly at 10:00 AM. We performed transcriptomic profiling by using a ribosomal tagging strategy to analyze POMC neuron-specific mRNA expression in vivo. We crossed Pomc-CreERT2 mice30 with Rpl22 floxed (RiboTag, Stock# 029977, The Jackson Laboratories) mice to generate Pomc-CreERT2; RiboTag mice, expressing a hemagglutinin A (HA)-tagged ribosomal protein in the POMC neurons upon tamoxifen injection.

Treatment ID:

TR002462

Treatment Summary:

We used the inducible Cre/loxP technology to generate mice in which UCP2 was selectively ablated in POMC neurons (Ucp2PomcKO mice). First, mice expressing a tamoxifen-inducible Cre recombinase (CreERT2) in cells expressing POMC (Pomc-CreERT2) were crossed with Rosa26-lox-stop-lox-tdTomato (Ai14; cre-recombinase-dependent expression) mice (Ai14 reporter mice; stock #007914; The Jackson Laboratory) to label POMC-expressing cells. Pomc-CreERT2; Rosa26-lox-stop-lox-tdTomato (Pomc-CreERT2; tdTomato) mice have POMC-expressing cells with the expression of tdTomato by tamoxifen administration. No observation of POMC-tdTomato expression was found in the absence of tamoxifen administration, indicating that recombination was strictly dependent upon tamoxifen-induced Cre recombinase activation. The mice with Pomc-CreERT2; tdTomato were then crossed with mice harboring conditional alleles Ucp2 floxed (Ucp2fl/fl; B6;129S-Ucp2tm2.1Lowl/J, Stock# 022394; The Jackson Laboratory) to generated mice with inducible deletion of Ucp2 specifically in POMC neurons (Ucp2PomcKO mice). All animal experiments were conducted with the mice expressing POMC-CreERT2. As control groups, Ucp2fl/fl; Pomc-CreERT2 mice were injected with tamoxifen, and Ucp2fl/fl; Pomc-CreERT2; tdTomato were mice injected with corn oil (vehicle), and Ucp2fl/fl; Pomc-CreERT2; tdTomato mice were injected intraperitoneally (IP) with tamoxifen (0.1 mg/g BW for 5 consecutive days) starting at 5 weeks of age to induce mature-onset deletion of Ucp2 in POMC neurons of Ucp2PomcKO mice. However, because there were no differences between these two control groups, most of the experiments were performed using Ucp2+/+; Pomc-CreERT2; tdTomato mice injected with tamoxifen (to label POMC neurons with tdTomato expression) as a control group, unless otherwise stated. Body composition was measured in vivo by MRI (EchoMRI; Echo Medical Systems, Houston, TX) monthly at 10:00 AM. We performed transcriptomic profiling by using a ribosomal tagging strategy to analyze POMC neuron-specific mRNA expression in vivo. We crossed Pomc-CreERT2 mice30 with Rpl22 floxed (RiboTag, Stock# 029977, The Jackson Laboratories) mice to generate Pomc-CreERT2; RiboTag mice, expressing a hemagglutinin A (HA)-tagged ribosomal protein in the POMC neurons upon tamoxifen injection.